IN THE SPECIFICATION:

Please insert the following new section at **page 38, between lines 14-15**:

--Deposits were made with American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA, 20110-2209, U.S.A. Deposit designations and dates of deposit are as follows: number 11 or 72 (produced by hybridomas ATCC PTA-2308 and PTA-2309, respectively, deposited July 28, 2000); F1-102 (produced by hybridoma ATCC PTA-3337, deposited April 24, 2001); F4-465 (produced by hybridoma ATCC PTA-3338, deposited April 24, 2001); F2-103 (ATCC PTA-3302 and PTA-3303, heavy and light chain, respectively, deposited April 19, 2001); F5-77 (ATCC PTA-3304 and PTA-3305, heavy and light chain, respectively, deposited April 19, 2001); and F5-157 (ATCC PTA-3306 and PTA-3307, heavy and light chain, respectively, deposited April 19, 2001).--

Please insert the "TM" symbol in the following section at **page 39, lines 17-24**, as indicated:

--Human CD40 cDNA was used as a template, and PCR was performed to amplify a fragment covering the extracellular domain of human CD40 with primers (5'-CCCAGATCTGTCCATCCAGAACCACCCACTGCATGCAGAG-3'; SEQ ID NO:1 and 5'-ACAAGATCTGGGCTCTACGTATCTCAGCCGATCCTGGGGAC-3'; SEQ ID NO:2) at 95°C for 5sec, 55°C for 30sec and 72°C for 30sec for 20 cycles. The amplified cDNA was inserted into pFastBac™ donor plasmids (Gibco BRL) at the 3'-end of a honeybee melityin signal peptide and at the 5' end of the Fc sequence of either human IgGl or mouse IgG2b.--

Please insert the "TM" symbol in the following section at **page 43, lines 6-8**, as indicated:

--The affinity of anti-CD40 antibody No.30 was determined by BiaCore™ analysis. Human CD40-mouse FC fusion protein was crosslinked to a sensor chip and the affinity was measured according to the manufacturer's protocol. The Kd value was 0.8-4nM.--

Please insert the "TM" symbols in the following section at **page 43, lines 23-29**, as indicated:

--Recombinant antibodies were produced by cloning immunoglobulin (Ig) genes from hybridomas that produce anti-human CD40 antibodies and expressed in mammalian cells. In brief, total RNA was purified from each of hybridomas F2-103, F5-77 and F5-157 using Tri-

Reagent™ according to the manufacturer's instructions (Molecular Research Center, Inc., Cincinnati, Ohio). Full length cDNA was synthesized from total RNA using the SMART RACE™ cDNA Amplification Kit (Clontech Laboratories, Inc., Palo Alto, CA) and Superscript II™ RT (GibcoBRL).--

Please insert the "TM" symbol in the following section at **page 44, lines 7-10**, as indicated:

--Full length PCR products were gel purified and blunt end ligated into SrfI cut PCR-Script™ (Stratagene, La Jolla, CA) or PCR-Blunt (Invitrogen, Carlsbad, CA) and sequenced by CFAR, Molecular Biology Core Facility (University of California, San Diego).--

Please insert the "TM" symbols in the following section at **page 46, lines 1-5**, as indicated:

--Expression plasmids were transiently transfected into Cos-1 cells by electroporation. Briefly, 3 x 10^6 cells were resuspended in 0.7 ml of serum-free DMEM containing 30 ug of plasmid DNA and placed into a 0.4 cm BioRad™ cuvette #165-2088. Cells were electroporated in a Gene Pulser II™ (BioRad™) set at 240 volts, capacitance=0.950 with a constant time of 15-25 msec.--

Please insert the "TM" symbols in the following section at **page 46, lines 8-9**, as indicated:

--Human antibodies were purified from culture media using Protein A sepharose™ 4 Fast Flow (Amersham #17-0618-02).--